Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer

  Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer

PR Newswire

WASHINGTON, April 17, 2013

WASHINGTON, April 17, 2013 /PRNewswire/ --Vanda Pharmaceuticals Inc. (Vanda)
(NASDAQ: VNDA), announced today that it has named Paolo Baroldi, M.D., Ph.D.
as its Senior Vice President and Chief Medical Officer.

Dr. Baroldi has over 30 years of clinical development experience in many
therapeutic areas, including neurology and psychiatry.He has been working in
the role of acting Chief Medical Officer with Vanda since October 1, 2012.

"We welcome Paolo to Vanda and look forward to his leadership in strengthening
our clinical organization," said Mihael H. Polymeropoulos, M.D., President and
Chief Executive Officer of Vanda.

Dr. Baroldi previously served as the Senior Vice President and Chief Medical
Officer of Vanda from July 2006 through January 2009. He has served in senior
clinical development positions at Galileo Research, Supernus Pharmaceuticals,
Chiesi Farmaceutici SpA, and Novartis AG.

Dr. Baroldi holds M.D. and Ph.D. degrees from the University of Milan, Italy
and is a member of the board of directors of Galileo Research.


Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the
development and commercialization of products for the treatment of central
nervous system disorders. For more on Vanda Pharmaceuticals Inc., please

Company Contact

Jim Kelly
Senior Vice President & Chief Financial Officer
Vanda Pharmaceuticals Inc.
(202) 734-3428

SOURCE Vanda Pharmaceuticals Inc.

Press spacebar to pause and continue. Press esc to stop.